Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

t to risks and uncertainties.  Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

    
                               DENDREON CORPORATION                       
                       CONSOLIDATED STATEMENTS OF OPERATIONS                  
                     (in thousands, except per share amounts)                 
                                                                              
                                     Three months ended    Twelve months ended
                                        December 31,           December 31, 
                                     ------------------    -------------------
                                     2009           2008      2009      2008 
                                     ----           ----      ----      ---- 
                                         (unaudited)       
'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:7/7/2015)... Texas (PRWEB) , ... July 07, 2015 , ... ... sensing technologies into everyday items, recently launched their first line of luxury smart ... today and is expected to ship this fall. , “The Socialite ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, raised ... surpassing their original 2015 fundraising goal by nearly $100,000, to help support ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... is debuting their brand new website. The website’s goal is to provide patients ... selection of patient tools, including requesting appointments online. , Part of the center’s ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the acquisition of ... people find the most fun activities to do with friends. , The acquisition of ... increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been a huge ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading audit, tax, and consulting ... to the community through company-wide volunteering efforts. , On an annual basis, in coordination ... assisting those in need throughout Baltimore and Washington D.C. , This year, ...
Breaking Medicine News(10 mins):Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... Pa., March 5 Secretary of Health Dr.,Calvin ... the Primary,Health Net Medical Clinic in Sharon and ... Edward G. Rendell,s plan to provide,access to health ... his "Cover All Pennsylvanians" proposal., "Access to ...
... Somanetics Corporation,(Nasdaq: SMTS ) will release its ... before the opening of the market on Tuesday, March,18, ... will host,a conference call that will be webcast live ... conference call, Bruce Barrett, Somanetics, president and chief,executive officer, ...
... and economic,changes are reshaping American shopping and eating ... new report from Packaged Facts. The,changing configuration of ... behavior. In fact, Packaged Facts reports that two ... home and eating out less.,Furthermore, they are looking ...
... Chiltern, a leading global research,organization, is proud to announce ... of the Year ceremony, including the coveted,Clinical Department of ... Gold: Clinical Department of the Year - Chiltern ... category Gold: Kara Tanabe in Clinical Research Associate ...
... reduced incidence by 70% , , WEDNESDAY, March 5 (HealthDay ... Oxalobacter formigenes reduces the risk of recurrent kidney stones ... The study looked at 247 adults with recurrent calcium oxalate ... of 259 adults. The researchers collected health and dietary information ...
... NEW YORK (March 5, 2008) -- Growing evidence shows that surgery ... only may change the way the disease is treated, but that ... article -- published in a special supplement to the February issue ... of diabetes surgery -- points to the small bowel as the ...
Cached Medicine News:Health News:Pennsylvania Health Secretary Visits Mercer County to Call for Health Insurance for All Pennsylvanians 2Health News:Somanetics Corporation to Release First Quarter 2008 Financial Results and Host Conference Call March 18, 2008 2Health News:Big Opportunities Are in the Bag for Food Retailers 2Health News:Chiltern Wins Top Prize 2Health News:Naturally Occurring Bacteria Cut Kidney Stone Recurrence 2Health News:Type 2 diabetes may be caused by intestinal dysfunction 2Health News:Type 2 diabetes may be caused by intestinal dysfunction 3Health News:Type 2 diabetes may be caused by intestinal dysfunction 4
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: